Acute respiratory infection caused by coronavirus. Acute upper respiratory infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Oral supplement with high dose of carnitine capsule (1000 mg / 3 times a day) in patients with acute pulmonary infection due to coronavirus in the intensive care un
Sponsors
Artesh University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients over 18 years Diagnosis of clinical and laboratory signs of severe Covid-19 Body mass index above 29.9 kg per square meter based on the weight in the file Completion of the informed consent form by the patient or his / her legal guardian Severe COVID-19 patients who are admitted to the medical ICU (MICU) and will require respiratory support Patients with normal GI function who receive enteral feeding
Exclusion criteria
Exclusion criteria: Receive any L-carnitine supplement in the last 6 months Participate in any other research project History of liver and kidney disease Pregnancy and lactation Any allergy to L-carnitine Patients who stayed in the ICU for < 72 hours Patients who receive parenteral nutritional support Patients treated with different drug regimens from the routine ICU protocol Patients will be ongoing treatment with cisplatin, phenobarbital, phenytoin, pivalic acid, valproic acid, ifosfamide, and levetiracetam Any gastrointestinal disorders that lead to stopping enteral feeding for more than 48 hours
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 28 days mortality. Timepoint: From the beginning of the intervention up to 28 days. Method of measurement: Record and view the file.;Serum level of acute phase reactive protein C. Timepoint: The beginning of the intervention and day 7. Method of measurement: Biochemically and using the appropriate kit.;Ratio of serum level of acute phase C-reactive protein to albumin. Timepoint: The beginning of the intervention and day 7. Method of measurement: Biochemically and using the appropriate kit.;ICU mortality. Timepoint: from beginning until ICU follow up. Method of measurement: Record and view the file.;The number of ventilator-dependent days. Timepoint: The beginning of the intervention until day 7. Method of measurement: Record and view the file. | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of stay in the ICU. Timepoint: beginning of intervention until 7 days later. Method of measurement: record and view of files.;Serum levels of neutrophils and lymphocytes. Timepoint: beginning of intervention and 7 days later. Method of measurement: By biochemical methods and related kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyyed Mostafa Arabi
Neyshabour University of Medical Sciences
Outcome results
None listed